OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
21
Results
Show all
Save search
Copy query
Show results for
Unknown
(21)
Publication Date
Release Date
2025
(3)
2011
(3)
2024
(2)
2023
(2)
2017
(2)
2014
(2)
2022
(1)
2021
(1)
2020
(1)
2019
(1)
2016
(1)
2015
(1)
2012
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Not available
S-EPMC3179254
|
biostudies-literature
Cite
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Not available
S-EPMC4451171
|
biostudies-literature
Cite
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Not available
S-EPMC7845943
|
biostudies-literature
Cite
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Not available
S-EPMC6865065
|
biostudies-literature
Cite
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Not available
S-EPMC3048920
|
biostudies-literature
Cite
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Not available
S-EPMC7310567
|
biostudies-literature
Cite
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Not available
S-EPMC3358820
|
biostudies-literature
Cite
Ceritinib in ALK-rearranged non-small-cell lung cancer.
Not available
S-EPMC4079055
|
biostudies-literature
Cite
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Not available
S-EPMC9928626
|
biostudies-literature
Cite
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Not available
S-EPMC4062100
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
